What to look Forward to in 2025 Research/Science 1/26/2025
Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.
View this post in the Community →
Similar Community Posts Join
5 / 11 resultscommunity I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community FOL005 claims it's better than Finasteride and Minoxidil.
FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.
community Status update on upcoming treatments
Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.
community Target Area Hair Count (TAHC) increase comparasion of all future treatments in clinical trial phases
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
community When will Breezula, SM04554, Follica FOL-004, follicum FOL-005 arrive in Canada?
The conversation is about the availability of hair loss treatments Breezula, SM04554, Follica FOL-004, and Follicum FOL-005 in Canada after FDA approval, including potential delays, loopholes for obtaining them, and insurance coverage.
Related Research
6 / 22 results
research A Novel Microparticle-Based Formulation for Topical Delivery of FOL-005, a Small Peptide
The new skin cream with FOL-005 safely promotes hair growth and is stable and user-friendly.
research Analysis of Mice Skin Distribution Using MALDI-MSI After Subcutaneous Injections of a Potent Novel Peptide Hair Growth Promoter, FOL-005
FOL-005, a hair growth promoter, acts locally on mouse skin where injected and could be a promising hair loss treatment.
research Analysis of Mice Skin Distribution Using MALDI-MSI After Subcutaneous Injections of a New Potent Inhibitor of Human Hair Growth, FOL-005
Some men don't respond to common hair loss treatments, but a new inhibitor, FOL-005, shows promise for targeting unwanted hair growth.
research Using MALDI-MSI Analysis to Study Distribution of FOL-005, a Potent, Novel Inhibitor of Human Hair Growth, After Subcutaneous Injection in Mice
FOL-005, a new substance, was found to reduce hair growth without toxicity when injected into skin, suggesting it could be used to treat excessive hair growth.
research Identification of an Osteopontin-Derived Peptide That Binds Neuropilin-1 and Activates Vascular Cells
FOL-026 peptide can help repair blood vessels and promote growth, offering potential treatment for vascular diseases.
research FGF7-Dependent Inhibition of Human Hair Growth by an Osteopontin-Derived Peptide: A Novel Solution for Hirsutism and Hypertrichosis
A new peptide, FOL-005, may help treat excessive hair growth by reducing a hair growth promoter, FGF7.